UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
___________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported):December 14, 2009
| GERON CORPORATION |
| (Exact name of registrant as specified in its charter) |
| Delaware | 0-20859 | 75-2287752 |
| (State or other jurisdiction | (Commission File Number) | (IRS Employer |
| of incorporation) | Identification No.) |
230 CONSTITUTION DRIVE
MENLO PARK, CALIFORNIA 94025
(Address of principal executive offices, including zip code)
(650) 473-7700
(Registrant's telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Compensatory Arrangements of Certain Officers
On December 14, 2009, the Compensation Committee of the Board of Directors of Geron Corporation (the “Company”) approved (a) annual base salaries for 2010, and (b) cash performance bonuses for 2009 for the following principal executive officer, principal financial officer and named executive officers of the Company:
| 2009 | ||||||
| Salary | 2010 | Cash | ||||
| Name and Position | Increase | Base Salary | Bonus | |||
| Thomas B. Okarma, Ph.D., M.D. | $ | — | $ | 535,000 | $ | 282,500 |
| President and CEO | ||||||
| David L. Greenwood | $ | — | $ | 415,000 | $ | 164,300 |
| Executive Vice President, CFO | ||||||
| Stephen M. Kelsey, M.D., F.R.C.P., F.R.C.Path. | $ | — | $ | 400,000 | $ | 158,400 |
| Executive Vice President, Chief Medical | ||||||
| Officer, Oncology | ||||||
| David J. Earp, J.D., Ph.D. | $ | — | $ | 325,000 | $ | 114,400 |
| Senior Vice President, Bus. Dev. and | ||||||
| Chief Patent Counsel | ||||||
| Melissa Kelly Behrs | $ | — | $ | 320,000 | $ | 112,600 |
| Senior Vice President, Therapeutic | ||||||
| Development, Oncology | ||||||
| Jane S. Lebkowski, Ph.D. | $ | — | $ | 335,000 | $ | 117,900 |
| Senior Vice President, Chief Scientific Officer, | ||||||
| Regenerative Medicine | ||||||
| Katherine E. Spink, Ph.D. | $ | 40,000 | $ | 260,000 | $ | 74,800 |
| Vice President Operations, Regenerative | ||||||
| Medicine | ||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| GERON CORPORATION | ||
| Date: December 15, 2009 | By: | /s/ David L. Greenwood |
| Name: | David L. Greenwood | |
| Title: | Executive Vice President, Chief Financial Officer | |